v3.26.3
Segment Report (Tables)
9 Months Ended
Sep. 30, 2026
Segment Reporting [Abstract]  
Schedule of Segment Information

Segment information for the three months ended September 30, 2026 is presented below:

  

   Pharmaceutical
Operations
   Premium
Nutritional
Supplements
   Total
Reportable
Segments
   Corporate
/ Other
   Total 
Revenue   -    13,942    13,942    -    13,942 
Cost of goods sold   -    4,334    4,334    -    4,334 
Research and development   3,892,387    -    3,892,387    -    3,892,387 
General and administrative   260,685    245,753    506,438    1,406,489    1,912,927 
Segment operating loss   (4,153,072)   (236,145)   (4,389,217)   (1,406,489)   (5,795,706)
Other income (expense), net   -    -    -    (1,428,364)   (1,428,364)
Net loss   (4,153,072)   (236,145)   (4,389,217)   (2,834,853)   (7,224,070)

 

Segment information for the nine months ended September 30, 2026 is presented below:

 

   Pharmaceutical
Operations
   Premium
Nutritional
Supplements
   Total
Reportable
Segments
   Corporate
/ Other
   Total 
Revenue   -    56,839    56,839    -    56,839 
Cost of goods sold   -    11,877    11,877    -    11,877 
Research and development   4,903,789    -    4,903,789    -    4,903,789 
General and administrative   966,216    1,102,279    2,068,495    3,574,329    5,642,824 
Segment operating loss   (5,870,005)   (1,057,317)   (6,927,322)   (3,574,329)   (10,501,651)
Other income (expense), net   -    -    -    (1,058,774)   (1,058,774)
Net loss   (5,870,005)   (1,057,317)   (6,927,322)   (4,633,103)   (11,560,425)